DNER and cancer: Thieno-diazepines similar to JQ1 are currently undergoing clinical trials for a number of different cancers (Matzuk et al. 2012, Benito et al. 2017) and therefore may have potential as a novel therapeutic compound for corticotrophinomas, although the specific pathways altered by this pan-BET inhibitor, especially in the pituitary, still remain to be fully elucidated (Andrieu et al. 2016).